enVVeno Medical offers to sell common stock

enVVeno Medical “announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. enVVeno expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and pre-funded warrants to be offered in this public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. enVVeno intends to use the net proceeds from the offering primarily for the continued development of its two lead products, VenoValve and enVVe, and for general corporate purposes, including working capital. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for this offering.”